Lack of enrollment
A Prospective, Randomized Study of the Artegraft vs Propaten Vascular Grafts for Renal Failure Patients Requiring Dialysis Access
Sponsor study identifier
interventional
1
1 country
1
Study Start
April 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2014
Actual (reported)Study Completion
November 2014
Actual (reported)Compare Artegraft and Propaten grafts for use in dialysis access to see if one performs better than the other. How long each one lasts until a complication arises or until the graft is no longer used will be compared. The study hypothesis is that the Artegraft, being an actual blood vessel, will work better than the manufactured Propaten graft.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 13, 2013
Actual (reported)March 28, 2014
Actual (reported)April 2014
Date type not reportedThis date has not been verified as actual or estimated.
November 2014
Actual (reported)November 2014
Actual (reported)July 14, 2016
Actual (reported)Primary Objective: The Primary Objective is to Assess the Primary, Primary Assisted and Secondary Patency Rate of Each Graft
The primary outcome will be determined by Kaplan-Meier life table analysis. Patency determination will be from access creation until the first occlusion of the graft.
12 months
Examine Incidence of Complications in Patients Receiving the Artegraft Bovine Graft vs. Gore Propaten Graft
12 months
Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Surgical placement of graft for hemodialysis access
Surgical placement of graft for hemodialysis access
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Kaiser Permanente Northwest
Portland, Oregon, 97232, United States
Earl Schuman, MD
Kaiser Permanente
1 participants (actual enrollment reported by the registry).
First Submitted
November 13, 2013
First Posted
March 28, 2014
Study Start
April 2014
Date type not reportedRelypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Primary Completion
November 2014
Actual (reported)Study Completion
November 2014
Actual (reported)Last Updated
May 15, 2019
Results First Posted
July 14, 2016
Record last verified: 2019-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: